Madrigal Pharmaceuticals

About

Madrigal Pharmaceuticals develops therapeutics to improve the lives of patients with metabolic and fatty liver diseases.

Conshohocken,Pennsylvania,United States
51 - 100
http://madrigalpharma.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $259M
Industries: Biotechnology,Medical Device,Pharmaceutical
Founded date: Jan 1, 2016
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:MDGL
Legal Name: Madrigal Pharmaceuticals, Inc.
Also Known As: VIA Pharmaceuticals

Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

6

$397.37M

Madrigal Pharmaceuticals has raised a total of $397.37M in funding over 2 rounds. Their latest funding was raised on Dec 21, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 21, 2022	Post-IPO Equity	$259M	—	—	—	Detail
May 9, 2022	Post-IPO Debt	$100M	1	Hercules Capital	—	Detail
Jul 5, 2017	Post-IPO Equity	$35M	—	—	—	Detail
May 2, 2016	Post-IPO Debt	$3.37M	—	—	—	Detail
Apr 1, 2014	Post-IPO Equity	—	1	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

5

0

Madrigal Pharmaceuticals has made 5 investments. Their most recent investment was on Dec 12, 2022, when Evertas raised $14M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 12, 2022 Evertas	Series A	$14M	Blockchain	—
Feb 24, 2022 Aligned	Seed	$34M	Blockchain	—
Apr 12, 2021 The Defiant	Pre-seed	$1.40M	Finance	—
Sep 11, 2020 BarnBridge	Seed	$1M	Bitcoin	—
Jan 31, 2020 Molecule	Pre-seed	—	Blockchain	—